Table 1 Demographic and baseline characteristics of the study population
Intervention period (n = 590) | Control period (n = 724) | P value | |
|---|---|---|---|
Male sex | 338 (57.3) | 439 (60.6) | 0.22 |
Age, mean ± SD | 66.1 ± 13.3 | 65.8 ± 13.5 | 0.69 |
Underlying diseases | |||
Solid cancer | 143 (24.2) | 183 (25.3) | 0.66 |
Hematologic malignancy | 33 (5.6) | 47 (6.5) | 0.46 |
Solid organ transplant | 34 (5.8) | 49 (6.8) | 0.46 |
Hematopoietic stem cell transplant | 9 (1.5) | 15 (2.1) | 0.46 |
End-stage renal disease, on dialysis | 33 (5.6) | 36 (5.0) | 0.62 |
Antibiotics used within the previous 3 months | |||
Cefazolin | 73 (12.4) | 79 (10.9) | 0.41 |
3rd cephalosporin | 95 (16.1) | 143 (19.8) | 0.09 |
Piperacillin/tazobactam | 177 (30.0) | 198 (27.3) | 0.29 |
Fluoroquinolone | 168 (28.5) | 198 (27.3) | 0.65 |
Carbapenem | 90 (15.3) | 120 (16.6) | 0.52 |
Glycopeptide (vancomycin or teicoplanin) | 113 (19.2) | 142 (19.6) | 0.83 |
Other | 180 (30.5) | 210 (29.0) | 0.55 |
ICU stay, days (mean ± SD) | 11.0 ± 12.0 | 11.2 ± 13.7 | 0.73 |